{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:57:19Z","timestamp":1790834239388,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012423","name":"Children's Healthcare of Atlanta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08CA248962"],"award-info":[{"award-number":["K08CA248962"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12HD072245"],"award-info":[{"award-number":["K12HD072245"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015241","name":"Society for the Study of Reproduction","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA138292"],"award-info":[{"award-number":["P30CA138292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016615","name":"Curing Kids Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002378"],"award-info":[{"award-number":["UL1TR002378"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011621","name":"Winship Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008258","name":"Hyundai Hope On Wheels","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008258","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jcyt.2020.09.010","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T09:22:34Z","timestamp":1604654554000},"page":"12-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"23","author":[{"given":"Jamie Y.","family":"Story","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaquelyn T.","family":"Zoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca E.","family":"Burnham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie A.G.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Trent","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Doering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil S.","family":"Raikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jcyt.2020.09.010_bib0001","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nri3384","article-title":"Six-of-the-best: unique contributions of gammadelta T cells to immunology","volume":"13","author":"Vantourout","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jcyt.2020.09.010_bib0002","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fimmu.2015.00015","article-title":"Five Layers of Receptor Signaling in gammadelta T-Cell Differentiation and Activation","volume":"6","author":"Ribeiro","year":"2015","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.jcyt.2020.09.010_bib0003","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nri3904","article-title":"Gammadelta T cells in cancer","volume":"15","author":"Silva-Santos","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2020.09.010_bib0004","doi-asserted-by":"crossref","first-page":"e22892","DOI":"10.4161\/onci.22892","article-title":"Tumor cell recognition by gammadelta T lymphocytes: T-cell receptor vs. NK-cell receptors","volume":"2","author":"Correia","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jcyt.2020.09.010_bib0005","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.3389\/fimmu.2017.01401","article-title":"Current Advances in gammadelta T Cell-Based Tumor Immunotherapy","volume":"8","author":"Lo Presti","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2020.09.010_bib0006","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3389\/fimmu.2018.00929","article-title":"Molecular Determinants of Target Cell Recognition by Human gammadelta T Cells","volume":"9","author":"Simoes","year":"2018","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.jcyt.2020.09.010_bib0007","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jcyt.2020.09.010_bib0008","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jcyt.2016.04.001","article-title":"Bioengineering and serum free expansion of blood-derived gammadelta T cells","volume":"18","author":"Sutton","year":"2016","journal-title":"Cytotherapy"},{"issue":"8","key":"10.1016\/j.jcyt.2020.09.010_bib0009","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1593804","article-title":"Ex vivo expanded patient-derived gammadelta T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model","volume":"8","author":"Zoine","year":"2019","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.jcyt.2020.09.010_bib0010","doi-asserted-by":"crossref","first-page":"8900","DOI":"10.18632\/oncotarget.13051","article-title":"Gammadelta T cells in cancer immunotherapy","volume":"8","author":"Zou","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.jcyt.2020.09.010_bib0011","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00262-006-0199-6","article-title":"Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study","volume":"56","author":"Kobayashi","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.jcyt.2020.09.010_bib0012","first-page":"575","article-title":"Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma","volume":"30","author":"Kobayashi","year":"2010","journal-title":"Anticancer Res"},{"issue":"8","key":"10.1016\/j.jcyt.2020.09.010_bib0013","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00262-011-1021-7","article-title":"Phase I\/II study of adoptive transfer of gammadelta T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma","volume":"60","author":"Kobayashi","year":"2011","journal-title":"Cancer Immunol Immunother"},{"issue":"15","key":"10.1016\/j.jcyt.2020.09.010_bib0014","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","article-title":"Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer","volume":"67","author":"Dieli","year":"2007","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.jcyt.2020.09.010_bib0015","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s00262-008-0491-8","article-title":"Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma","volume":"57","author":"Bennouna","year":"2008","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"10.1016\/j.jcyt.2020.09.010_bib0016","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00262-011-1049-8","article-title":"Pilot trial of interleukin-2 and zoledronic acid to augment gammadelta T cells as treatment for patients with refractory renal cell carcinoma","volume":"60","author":"Lang","year":"2011","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.jcyt.2020.09.010_bib0017","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.4049\/jimmunol.174.3.1338","article-title":"Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma","volume":"174","author":"Viey","year":"2005","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.jcyt.2020.09.010_bib0018","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.exphem.2009.04.008","article-title":"Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma","volume":"37","author":"Abe","year":"2009","journal-title":"Exp Hematol"},{"issue":"5","key":"10.1016\/j.jcyt.2020.09.010_bib0019","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-07-2973","article-title":"Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors","volume":"68","author":"Vales-Gomez","year":"2008","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.jcyt.2020.09.010_bib0020","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-07-4744","article-title":"Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma","volume":"14","author":"Armeanu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2020.09.010_bib0021","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/178698","article-title":"NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma","volume":"2015","author":"Fionda","year":"2015","journal-title":"Biomed Res Int"},{"issue":"4","key":"10.1016\/j.jcyt.2020.09.010_bib0022","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.18632\/oncotarget.13979","article-title":"Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and gammadelta T cell-mediated lysis in multiple myeloma","volume":"8","author":"Niu","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.jcyt.2020.09.010_bib0023","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jcyt.2014.03.008","article-title":"Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity","volume":"16","author":"Satwani","year":"2014","journal-title":"Cytotherapy"},{"issue":"12","key":"10.1016\/j.jcyt.2020.09.010_bib0024","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1593\/neo.08972","article-title":"Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells","volume":"10","author":"Ogbomo","year":"2008","journal-title":"Neoplasia"},{"issue":"6","key":"10.1016\/j.jcyt.2020.09.010_bib0025","first-page":"2241","article-title":"Cancer immunotherapy using NKG2D and DNAM-1 systems","volume":"32","author":"Morisaki","year":"2012","journal-title":"Anticancer Res"},{"issue":"23","key":"10.1016\/j.jcyt.2020.09.010_bib0026","doi-asserted-by":"crossref","first-page":"11136","DOI":"10.1158\/0008-5472.CAN-05-0599","article-title":"Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B","volume":"65","author":"Skov","year":"2005","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.jcyt.2020.09.010_bib0027","first-page":"2505","article-title":"Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA\/B system","volume":"31","author":"Morisaki","year":"2011","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.jcyt.2020.09.010_bib0028","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-017-0519-7","article-title":"Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia","volume":"10","author":"Fan","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.jcyt.2020.09.010_bib0029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11864-017-0456-2","article-title":"Treatment of Relapsed\/Refractory Acute Myeloid Leukemia","volume":"18","author":"Bose","year":"2017","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"10.1016\/j.jcyt.2020.09.010_bib0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019001239","article-title":"How I treat acute myeloid leukemia in the era of new drugs","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jcyt.2020.09.010_bib0031","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0955-0674(95)80031-X","article-title":"Ubiquitin, proteasomes, and the regulation of intracellular protein degradation","volume":"7","author":"Hochstrasser","year":"1995","journal-title":"Curr Opin Cell Biol"},{"issue":"5","key":"10.1016\/j.jcyt.2020.09.010_bib0032","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.jcyt.2020.09.010_bib0033","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","article-title":"Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions","volume":"12","author":"Fleischer","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.jcyt.2020.09.010_bib0034","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40262-012-0010-0","article-title":"Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma","volume":"51","author":"Moreau","year":"2012","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.jcyt.2020.09.010_bib0035","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00280-010-1283-3","article-title":"Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma","volume":"67","author":"Reece","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.jcyt.2020.09.010_bib0036","first-page":"273","article-title":"Review. Clinical pharmacokinetics of bortezomib","volume":"21","author":"Leveque","year":"2007","journal-title":"In Vivo"},{"issue":"2","key":"10.1016\/j.jcyt.2020.09.010_bib0037","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3324\/haematol.2012.063602","article-title":"Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups","volume":"98","author":"Pulte","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2020.09.010_bib0038","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1038\/srep04227","article-title":"Survival improvement by decade of patients aged 0\u201314 years with acute lymphoblastic leukemia: a SEER analysis","volume":"4","author":"Ma","year":"2014","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.jcyt.2020.09.010_bib0039","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.3390\/ijms20123021","article-title":"Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia","volume":"20","author":"Follini","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2020.09.010_bib0040","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.2147\/OTT.S191621","article-title":"Mechanisms of drug resistance in acute myeloid leukemia","volume":"12","author":"Zhang","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10.1016\/j.jcyt.2020.09.010_bib0041","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12967-017-1378-2","article-title":"Gamma-delta (gammadelta) T cells: friend or foe in cancer development","volume":"16","author":"Zhao","year":"2018","journal-title":"J Transl Med"},{"issue":"6","key":"10.1016\/j.jcyt.2020.09.010_bib0042","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.4049\/jimmunol.0901334","article-title":"Cutting edge: TGF-beta1 and IL-15 Induce FOXP3+ gammadelta regulatory T cells in the presence of antigen stimulation","volume":"183","author":"Casetti","year":"2009","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2020.09.010_bib0043","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2011-01-331298","article-title":"Differentiation, phenotype, and function of interleukin-17-producing human Vgamma9Vdelta2 T cells","volume":"118","author":"Caccamo","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jcyt.2020.09.010_bib0044","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.4049\/jimmunol.1103710","article-title":"Human Vgamma9Vdelta2 T cells specifically recognize and kill acute myeloid leukemic blasts","volume":"188","author":"Gertner-Dardenne","year":"2012","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.jcyt.2020.09.010_bib0045","first-page":"4509","article-title":"The antitumour effect of {gamma}{delta} T-cells is enhanced by valproic acid-induced up-regulation of NKG2D ligands","volume":"30","author":"Suzuki","year":"2010","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.jcyt.2020.09.010_bib0046","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"issue":"399","key":"10.1016\/j.jcyt.2020.09.010_bib0047","doi-asserted-by":"crossref","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.jcyt.2020.09.010_bib0048","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.3324\/haematol.2017.183459","article-title":"Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma","volume":"103","author":"Shalabi","year":"2018","journal-title":"Haematologica"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324920309014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324920309014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:41:53Z","timestamp":1761442913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324920309014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1465324920309014"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2020.09.010","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2020.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}